AbbVie's eczema drug shows benefit in Phase 2; BioMarin lays off 117
Plus news about Sarepta, Rafael Holdings, Sagimet, Pyxis Oncology, Connect Biopharma, Asahi Kasei, Astrocyte Pharmaceuticals, GSK, Wave and Kailera. AbbVie unveils Phase 2 data for Apogee drug: Zumilokibart, an anti-IL-13 antibody, produced statistically significant benefits ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.